stockrow
Friday 6 November 2026
Export EPRX’s income statement to Excel — free account
Eupraxia Pharmaceuticals Inc.
EPRX Healthcare Biotechnology
- EPS
- +11.5%
- Free cash flow
- −56.4%
Quarter to June 2026, against a year earlier
6.83
0.23
+3.48%
Follow EPRX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 | 1 | +61.3% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (19) | (29) | (26) | (39) | (50) | +26.7% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (19) | (29) | (26) | (39) | (50) | +26.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (0.98) | (1.17) | (0.76) | (1.03) | (0.99) | +1.5% | ||||||
| Cash flow | — | — | — | — | — | — | (0.75) | (0.86) | (0.88) | (0.71) | (0.57) | (1.4%) | ||||||
| Capex | — | — | — | — | — | — | (0.01) | 0.00 | 0.00 | (0.01) | (0.01) | +6.4% | ||||||
| Free cash flow | — | — | — | — | — | — | (0.76) | (0.86) | (0.89) | (0.73) | (0.58) | (1.3%) | ||||||
| Book value | — | — | — | — | — | — | 0.37 | 0.04 | 0.94 | 2.01 | 1.96 | +75.3% | ||||||
| Shares, m | — | — | — | — | — | — | 19 | 24 | 34 | 40 | 50 | +27.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (14) | (21) | (30) | (29) | (37) | +25.6% | |||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | (1) | (1) | +35.8% | ||||||
| Free cash flow | — | — | — | — | — | — | (15) | (21) | (30) | (29) | (38) | +25.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 16 | 0 | 31 | 79 | 128 | +72.3% | |||||
| Net debt | — | — | — | — | — | — | (9) | (9) | (33) | (80) | (132) | +105.1% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | 7 | 1 | 32 | 80 | 130 | +123.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (143.29) | (93.93) | (67.89) | (64.44) | (67.9) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | (696.79) | (5,054.21) | (161.71) | (117.82) | (161.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 29 | 33 | 49 | — | +30.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
Eupraxia Pharmaceuticals Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics Inc. | $451.2M | — (loss-making) | — | — | n/m | −201.41% (below 0%: shrinking) | — | 0.00% | Compare |
| STTK Shattuck Labs, Inc. | $450.6M | — (loss-making) | — (loss-making) | −10.31% (below 0%: shrinking) | n/m | +1.01% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EPRX Eupraxia Pharmaceuticals Inc. | $429.1M | — (loss-making) | — | — | n/m | −56.41% (below 0%: shrinking) | — | 0.00% | |
| ARVN Arvinas, Inc. | $428.9M | — (loss-making) | — (loss-making) | −98.81% (below 0%: shrinking) | n/m | +82.77% (above 0%: growing) | 80.00% | (11,820.00%) | Compare |
| GYRE Gyre Therapeutics, Inc. | $425.2M | — (loss-making) | — (loss-making) | +7.75% (above 0%: growing) | n/m | −129.91% (below 0%: shrinking) | 94.09% | 0.00% | Compare |
| PRTCY PureTech Health PLC Sponsored ADR | $424.0M | — (loss-making) | — (loss-making) | −44.60% (below 0%: shrinking) | +66.43% (above 0%: growing) | +19.27% (above 0%: growing) | 2.83% | 0.00% | Compare |
| OCS Oculis Holding AG | $421.6M | — (loss-making) | — (loss-making) | −97.17% (below 0%: shrinking) | n/m | −20.85% (below 0%: shrinking) | 100.00% | (338,436.05%) | Compare |
| PHAT Phathom Pharmaceuticals, Inc. | $413.0M | — (loss-making) | — (loss-making) | +71.14% (above 0%: growing) | n/m | +112.23% (above 0%: growing) | 78.32% | (0.10%) | Compare |
| CRMD CorMedix Inc | $407.6M | 2.2× | 11.5× | +156.52% (above 0%: growing) | +13.79% (above 0%: growing) | +185.90% (above 0%: growing) | 75.66% | 42.10% | Compare |
| Median of peers | $424.6M | — | — | −10.31% | — | +10.14% | 80.00% | 0.00% |